Skip to main content
. 2017 Sep 11;34(3):233–238. doi: 10.1055/s-0037-1604296

Fig. 1.

Fig. 1

Hyperactivation of the RAS/MAPK or PI3K/AKT/mTOR pathways seen in the majority of vascular anomalies. Schematic of the two pathways displays location of associated protein with names of disorders in boxes. Proteins with loss-of-function mutations indicated in red; those with gain of function in green. Rapamycin (in bright red) is a mammalian target of rapamycin (mTOR) inhibitor effective in treating VMs and LMs.